Urinary Patient Articles & Analysis
12 news found
LP-10 pharmacokinetic analysis demonstrated short duration of systemic uptake, decreased cystoscopic bleeding and ulceration sites, and improved patients’ urinary symptoms. ...
Mera Medical Solutions will take advantage of the MEDICA showcaseto launch Harex® , a Premium device for the Control of Male Urinary Incontinence, worldwide. Harex® is assuming a substantial improvement in the quality of life of patients with Urinary Incontinence. ...
XFLO offers a reversible and office-based treatment option for patients who are seeking immediate relief from lower urinary tract symptoms (LUTS) caused by BPH without compromising sexual function. ...
Caldera Medical, a medical device company that develops best-in-class surgical products for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse, and Polyps announced the launch of Desara® TVez, an expansion to their Desara® Family of products. “Staying true to our commitment of being surgeon and patient focused, Caldera Medical ...
Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it will begin enrollment in its pivotal clinical trial (SANS-UUI), a single-arm study that will enroll 145 patients at 25 sites globally. The study will evaluate the safety and efficacy of Neuspera’s Nuvella™ system ...
Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced the successful completion of patient enrollment in the OASIS pivotal clinical study that will be the basis by which the company will seek US-FDA (Food & Drug Administration) marketing clearance in ...
Recent results from Zenflow’s pilot studies showed that at 12 months, patients displayed statistically significant symptom relief, including improved quality of life scores and increases in maximum urinary flow rates. ...
Data includes preliminary results from 39 patients at 4 centers across 3 countries – the temporary implant demonstrated the procedure was safe and provided immediate and sustained symptom relief. ...
Of these patients, 38 completed their 12-month follow up and showed statistically significant improvements in symptoms, including the following, which were all compared to baseline: 50% improvement in mean International Prostate Symptom Score (IPSS) 64% improvement in mean quality of life (QoL) score 60% improvement in mean maximum urinary flow rate (Qmax). ...
The study demonstrated high stability of urinary exosomes and reliability in monitoring patients for allograft rejection. ...
Over 40 million patients suffer from BPH in the U.S. alone. “The Zenflow Spring clinical trial data thus far demonstrates promising outcomes with respect to patient symptom relief, urinary flow rates, and preservation of sexual function,” said Dr. ...
The idea is simple: when a patient has a bacterial infection, doctors should find out what kind of bacteria it is so they can give the most effective treatment. ...